Safety and Reactogenicity of GSK Biologicals' dTaP Vaccine (Boostrix) in Healthy Vietnamese Children

Trial Profile

Safety and Reactogenicity of GSK Biologicals' dTaP Vaccine (Boostrix) in Healthy Vietnamese Children

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Jul 2016 Results published in the Vaccine
    • 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Mar 2014 Planned End Date changed from 1 May 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top